MapLight Therapeutics, Inc. 8-K

What Happened MapLight Therapeutics, Inc. filed an 8-K reporting the results of its annual meeting held June 23, 2026. Of 42,610,079 shares outstanding as of the record date, 36,883,750 shares (about 86.56%) were present or represented by proxy. Stockholders elected three director nominees and ratified the selection of RSM US LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Record and attendance: 42,610,079 shares outstanding; 36,883,750 shares present or represented (≈86.56% turnout).
• Director elections (terms through 2029):
  • Martin Babler — For: 31,424,194; Withheld: 3,575,737
  • Troy Cox — For: 34,979,012; Withheld: 20,919
  • George Pavlov — For: 34,220,342; Withheld: 779,589
  • Broker non-votes: 1,883,819
• Auditor ratification: RSM US LLP selected for fiscal year ending Dec 31, 2026 — For: 36,859,217; Against: 22,332; Abstained: 2,201; Broker non-votes: 0.

Why It Matters The vote confirms the company’s board slate and maintains continuity in governance through 2029 for the elected directors. Ratifying RSM US LLP establishes the independent auditor for fiscal 2026, which affects financial reporting and audit continuity. High shareholder turnout (≈86.6%) indicates broad participation in these governance decisions.